Praxis Precision Medicines, Inc.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $0
- Net income
- -$303.3M
- Total assets
- $937.9M
- Market cap
- $7.1B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $326.2M
- Operating income
- -$326.2M
- Income tax
- $471.0K
- Net income
- -$303.3M
- EPS (basic)
- $-13.48
- EPS (diluted)
- $-13.48
Balance sheet
- Total assets
- $937.9M
- Current assets
- $610.9M
- Total liabilities
- $59.8M
- Current liabilities
- $59.8M
- Shareholders’ equity
- $878.1M
Cash flow
- Operating cash flow
- -$249.1M
- Investing cash flow
- -$311.1M
- Financing cash flow
- $702.2M
- Net cash flow
- $142.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $7.1B
- EPS (diluted)
- $-13.48
- Shares outstanding
- 28.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $303.3M in FY2025.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Praxis Precision Medicines, Inc..
Write a review
News about Praxis Precision Medicines, Inc.
News & sentiment via Polygon.io
